A Phase 1 study was performed to evaluate safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the selective histamine H 4 receptor antagonist SENS-111, an oral small molecule.
Introduction
Histamine receptors are potent molecular targets which play an important role in modulating vestibular functions.-Histamine activation can be blocked by specific receptor antagonists [1] . Type-1 histamine (H 1 ) receptor antagonists, such as meclizine [2] are frequently used to treat vestibular dysfunction, including notably acute unilateral vestibulopathy (AUV) or motion sickness; however, their use is limited by the resulting sedation which reduces or delays central compensation. Betahistine acts against both H 1 receptors and type-3 histamine (H 3 ) receptors with a yet-to-be deciphered mechanism of action, accelerating vestibular compensation [3] . Recent attention has focused on the type-4 histamine (H 4 ) receptor, which is expressed in mammalian vestibular primary neurons [4] [5] [6] . A pronounced inhibitory effect on vestibular neuron activity was seen in vitro and ex vivo in the presence of two selective H 4 receptor antagonists. Furthermore, when administered in vivo to rats suffering from unilateral vestibular lesions, these antagonists were found to alleviate vertigo symptoms. These data support the targeting of H 4 receptor signalling as a potential avenue for treating vestibular disorders.
SENS-111 (Seliforant; 2-isobutyl-6-(3 methylamino) azetidin-1-yl) pyrimidin-4-amine), a novel oral small molecule, is a selective H 4 receptor antagonist. To date, it has been administered in over 170 healthy volunteers. Here we report a clinical Phase 1 study carried out to determine the safety, tolerability and pharmacokinetics (PK) profile of SENS-111 administered as single and multiple ascending doses in healthy volunteers. As a non-sedative H 4 receptor antagonist, it is anticipated that SENS-111 can play a clinical role in the relief of vertigo symptoms in vestibular diseases, including AUV. In order to confirm data observed in vitro and in vivo, we conducted a clinical study where the effects of SENS-111 on nystagmus and vertigo induced via caloric irrigation were evaluated in healthy subjects. Population PK and pharmacokinetic/pharmacodynamic (PK/PD) models were developed, and a PK/PD analysis was conducted to develop criteria for dose selection and to optimize the later-phase clinical development plan.
Methods

Study design
A randomized placebo-controlled, double-blind study was performed in healthy volunteers with three sequential substudies, a single-ascending-dose (SAD) and two multiple-ascending-dose (MAD) studies. The study was conducted at Eurofins Optimed (Gieres, France), and was registered as EudraCT No. 2014-004056-65. It was approved by the local ethics committee and carried out in accordance with the Declaration of Helsinki, Good Clinical Practice and national regulations. All subjects signed written informed consent prior to any study procedures.
Initially, single ascending doses of SENS-111 (100, 200, 300, 400, 500 mg) or placebo were administered sequentially to cohorts of eight subjects (six test, two placebo per dose level). Two sequential multiple-ascending-dose studies of SENS-111 or placebo were then performed in cohorts of 12 subjects (nine test, three placebo per dose level). In the first of these, SENS-111 (50, 100, 150 mg day À1 ) or placebo was administered for four consecutive days, and in the second SENS-111 (200, 250 mg day À1 ) or placebo was administered for seven consecutive days. Subjects were followed-up for 7-9 days after the last dose. SENS-111 and matched placebo were taken orally once daily in the morning, under fasted conditions. Subjects received standardized meals, exercise was restricted and smoking was prohibited. Adverse events (AEs) and physical examination evaluations were recorded throughout the study. Vital signs and ECG assessments were performed at baseline, on the day(s) of dosing (predose and~2.5-3 h later for all doses, and 12 h later for the ≥300 mg single doses), and at the end of study. Laboratory parameters were evaluated at baseline, then every 2 days up to Days 4, 6 and 10 for the three sequential studies respectively, and at the end of study. The decision to increase the dose to the next dose level was made after the Data Safety Monitoring Board (DSMB; consisting of sponsor representatives, investigators, pharmacovigilance and ENT specialists) performed a blinded review of safety/tolerability and PK data of at least six out of eight subjects of a given dose level for up to at least 48 h post-dose. A decision could be made to add more subjects at the same dose level or investigate intermediate dose levels. Given that toxicity studies identified potential neurological toxic effects at very high doses and concentrations, the DSMB considered it safer to limit doses to maximum doses of 500 mg single administration and 250 mg once daily for 7 days, to maintain a large safety margin.
The primary objective was to establish the safety and tolerance profile of SENS-111 when administered as single or multiple ascending doses. Secondary objectives were to characterize the PK properties of SENS-111 and its metabolites, and the relationship between SENS-111 exposure and its effect on nystagmus and vertigo (in the MAD studies).
Dose rationale
Previous in-vitro experiments showed that SENS-111 antagonizes H 4 receptor activity in the inner ear at concentrations corresponding to human plasma concentrations of 60-150 ng ml À1 . In-vivo experiments in a range of pharmacologic models (mice, rat and monkey asthma models, rat vestibular deficiency model) showed that SENS-111 is active at doses corresponding to human plasma concentrations of 100-500 ng ml À1 . H 4 blockade was previously evaluated in a first-in-human single-dose study in healthy volunteers (via ex-vivo measurement of eosinophil shape change after histamine stimulation) and correlated with SENS-111 plasma concentrations, with SENS-111 doses from 2 mg to 100 mg. Maximum PD effects were seen at 60-100 mg with mean plasma C max of 70-120 ng ml
À1
respectively. Given that SENS-111 concentrations in the inner ear are one-third of plasma concentration in animal models, plasma concentrations of 210-360 ng ml À1 were expected to give significant H 4 blockade in the inner ear. While single doses of 100 mg were safe in the previous clinical study, in the current SAD study, the 100 mg dose was repeated as a safety precaution, with planned escalation up to 400 mg. The 500 mg dose was added subsequently based on the safe profile at lower doses. The study design allowed for the planned MAD doses (50-150 mg day À1 in the 4-day study and 200 mg day
in the 7-day study per DSMB) to be refined according to the results of the SAD study. In the 7-day MAD study, if the average exposure in the 200 mg cohort was lower than that observed in the 400 mg SAD cohort, a cohort of 250 mg day À1 was planned. The maximal 7-day MAD dose tested was fixed at half the maximal tolerated dose in the SAD study.
Subjects
For all three SAD and MAD studies, men aged 18-45 years, non-smokers or smokers of ≤5 cigarettes/day, with a body mass index (BMI) of between 18.5 and 28.5 kg m À2 , normal dietary habits, and without any clinically relevant abnormalities, and using adequate contraceptive measures were eligible. Women aged 45-65 years who were not of childbearing potential and who fulfilled these criteria were eligible for the last cohort of SAD and the final two cohorts of the 7-day MAD study. For all subjects, the main exclusion criteria were a history of ear/head trauma, ophthalmic surgery, history of or current deafness, family history of deafness, vestibular 
Vestibular dysfunction assessment
A modified caloric test was performed to evaluate the effects of SENS-111 on nystagmus and vertigo, signs of vestibular dysfunction. The right ear was irrigated with water (25°C, 250 ml min À1 ) until a nystagmus peak slow phase velocity (SPV) of at least 20°s À1 was reached during the culmination phase.
The caloric test was performed for the MAD sub-study, three times at 3-h intervals on Day À1 (baseline). It was performed only once daily 2-3 h post-dose from Days 1 to 4, and at 2 h post-dose on Day 7 for the 7-day MAD study to record vertigo latency (appearance and disappearance) and duration.
Nystagmus was recorded by videonystagmography using a mono-camera videonystagmograph. Culmination was considered the maximum SPV value. Online automatic detection of maximal SPV was deduced from the slow phase cumulative curve (desaccaded nystagmus) over 2 s, according to the formula SPV (t) = (Cum [+1 s] -Cum [À1 s])/2. Subjects were required to look directly ahead and wore an eye mask to avoid visual fixation and counted down during recording to standardize their level of vigilance. Recording lasted up to 5 min after irrigation and was stopped earlier if eye movement speed was 0 for 2 min.
Vertigo intensity was measured using a visual analogue scale (VAS; 0-10, 0 being none) within 5 min after the end of the caloric irrigation. Vestibular syndrome was evaluated in terms of illusion of movement, duration of the illusion, motion intolerance, neurovegetative signs and instability using the physician-administered European Evaluation of Vertigo (EEV) questionnaire (0-4, 0 being none) [7] , 5 min after the end of the caloric irrigation.
As there was a marked intraindividual variability (for example, SPV had an intraindividual variability at baseline ranging from 2% to 84% in healthy subjects), the mean value of the three assessments was used as the baseline value for all nystagmus and vertigo variables.
Population PK and PK/PD modelling
A nonlinear mixed-effects approach was used to develop population PK and PK/PD models, to evaluate the relationship between exposure and PD markers (nystagmus and vertigo parameters) and provide a rationale for dose selection in late-phase clinical development.
Model development strategy. Model development was based on two sequential steps: (1) development of a population PK model exploring alternative absorption and disposition modelling approaches to account for single and repeated dose administrations, and (2) exploration of alternative population PK/PD models for characterizing the exposureresponse relationship between SENS-111 and PD marker outcomes of SPV peak at culmination and nystagmus frequency, latency of nystagmus culmination, latency of onset of a nystagmus (defined by SPV >2°s À1 ), duration of nystagmus, latency of onset/offset and duration of vertigo sensation, vertigo intensity and EEV.
Population PK model building. Different models (including first and zero order processes) were evaluated to characterize SENS-111 absorption, and the first-order process was the best performing model. The inter-individual variability (IIV) model (random effect) described the unexplained random variability in individual values of structural model parameters (fixed effect). It was assumed that the IIV of the PK parameters was log-normally distributed (random effect).
A two-compartment model was ultimately retained. It was characterized by a central compartment, and peripheral distribution compartments with first-order absorption, distribution and elimination rate constants described the PK of SENS-111. The model parameters were clearance (estimated assuming bioavailability of 1), central volume (estimated assuming bioavailability of 1), inter-compartmental clearance, peripheral volume, absorption rate constant and absorption lag time.
The covariate analysis was conducted to evaluate the potential impact of dose and time on clearance (CL) and volume (V). The following models were evaluated:
where CL and V are for the dose of 50 mg, and at Day 1, DosCL and TimCL and DosV and TimV are parameters characterizing the change in CL and V as a function of the dose and time, respectively.
Population PK/PD model building. An indirect modelling approach was used to characterize the exposure-response relationship, assuming that a measured response (R) may be produced by indirect mechanisms; for example, factors controlling the input or production (k in ) of the response variable may be either inhibited or stimulated, or determinants of loss (k out ) of the response variable may be inhibited or stimulated.
The rate of change of the response (R) over time for subjects treated with placebo was described by:
where k in represents the zero-order constant for production of the response and k out defines the first-order rate constant for loss of the response. As the system is assumed to be stationary, the response variable (R) begins at a predetermined baseline value (Bas), changes with time and returns to Bas. Thus:
In the presence of SENS-111 the PD response was described by:
where F1 and F2 are the drug-related model components affecting the k in and k out values. For latency of vertigo appearance, SENS-111 was assumed to stimulate k in (positive response) and k out (negative response) at different levels of exposure according to the following functions:
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where Cp represents the model-predicted time-varying plasma concentration of SENS-111. For duration of vertigo and latency of vertigo disappearance, SENS-111 was assumed to inhibit k in and k out at different levels of exposure according to the following functions:
The indirect-response model parameters describing the placebo and SENS-111 responses were simultaneously estimated by jointly fitting the placebo and the drug-related PD measurements for each PD measurements considered.
Modelling options. The relationship between a PK parameter (P) and its variance can be expressed as:
where P j is the value of the PK parameter for the jth individual, P TV is the typical value of P for the population, and ηp denotes the difference between P j and P TV , independently, which was identically distributed with a mean of zero and variance of ωp 2 .
The residual variability, which comprised, but is not limited to, IIV, experimental errors, process noise and/or model misspecifications, was modelled using a combined error structures as: y ij = y tij (1 + ε 1ij ) + ε 2ij . y ij represents the jth observation in the ith individual, y tij represents the corresponding model prediction, and ε 1ij (or ε 2ij ) is a normally distributed random error with a mean of zero and a variance of σ2.
Evaluation of population models. Model selection was based on physiological and pharmacological rationale and the principle of parsimony. Model discrimination was based on several criteria. For each analysis, the improvement in model goodness-of-fit and significance of additional parameters were assessed with: (i) the likelihood ratio test (LRT). Significant improvement in model fit was assessed by the change in the minimum objective function values (OFV). Minimization of the test and the reference models OFV (i.e., ΔOFV = [OFV test -OFV reference ]) is proportional to a change in À2 log likelihood and is chi-squared (χ 2 ) distributed. The LRT was used to evaluate the statistical significance of nested models; and (ii) the Akaike Information Criterion (AIC).
Model performance. Model performance/validation and stability were assessed using goodness-of-fit plots, and visual predictive checks (VPC). Goodness-of-fit plots were generated including observed data vs. individual and modelpredicted concentrations, absolute-weighed residuals vs. individual predictions, and conditional-weighted residuals vs. time. Adequacy of the final model was evaluated with VPC, including the effects of statistically significant covariates. Two hundred replicates of the original dataset were simulated based on the final model. The 5th, 50th and 95th percentiles of the observed data were computed using the simulated data together with their 95% confidence intervals. Statistics were calculated from simulated and observed data for comparison. Distributions of quantiles of simulated data were compared to observed data quantiles.
Simulation
PK/PD model for vertigo duration and latency of vertigo appearance and disappearance was used to estimate response by simulating the treatment response using Monte Carlo simulation. Plots of the median SENS-111 concentration with the prediction intervals and median change from baseline of the duration of vertigo and the latency of vertigo appearance with the prediction intervals were generated.
Statistical methods
Safety was analysed in all subjects who received at least one dose of SENS-111. AEs were coded using MedDRA, v17. Changes of SPV peak at culmination, frequency and latency of nystagmus appearance, latency of nystagmus culmination and disappearance and duration from baseline to 2-h posttreatment for Days 1-4 (and Day 7 for the 7-day MAD study) were analysed by analysis of covariance. Active doses were compared from the mixed linear model using a Tukey adjustment [8] . A repeated-measures mixed linear model was used with treatment/dose group, time and baseline value as fixed effects and subject as a random effect. If the residual distribution was not normal (Shapiro-Wilk test), log transformation was applied (before change). If a normal hypothesis was not demonstrated, rank data were retained. For vertigo, latency, duration, and intensity were analysed with the same caloric test. The EEV was analysed with a GENMOD generalized linear model (five items with five categorical modalities each), and the total EEV score was analysed by a repeated measures analysis of variance model. A significance threshold of P = 0.05 was used. Non-compartmental PK analyses were performed with Kinetica (v4.3), PK/PD population analyses using R (v3. 
Nomenclature of targets and ligands
Key protein targets and ligands in this article are hyperlinked to corresponding entries in http://www.guidetopharmacology.org, the common portal for data from the IUPHAR/ BPS Guide to PHARMACOLOGY [10] , and are permanently archived in the Concise Guide to PHARMACOLOGY 2017/18 [11] .
Results
Subject population
Overall, 100 subjects were randomized and received at least one dose of SENS-111 (n = 75) or placebo (n = 25) and completed the study; 40 subjects (30 SENS-111, 10 placebo) including 28 males were treated in the SAD study, 36 (n = 27 SENS-111, n = 9 placebo) in the 4-day MAD all of whom were male, and 24 (n = 18 SENS-111, n = 6 placebo) in the 7-day MAD including 12 males. Demographics were comparable between the three sub-study populations; mean age was between 29 and 44 years (range 19-65), mean BMI was between 23.1 and 24.1 kg m À2 (range 18.9-29.0), and most subjects were Caucasian (81 subjects; 81%) or black (17 subjects; 17%).
Safety
Single and multiple doses of SENS-111 up to 250 mg were well tolerated and a maximal tolerated dose was not reached. AEs were reported in nine subjects (23%, four of whom received placebo) in the SAD study, seven subjects (19%, two of whom received placebo) in the 4-day MAD study, and three subjects (13%, one of whom received placebo) in the 7-day MAD study (Table 1 ). All AEs were mild to moderate, and resolved before study end. Few AEs were considered related; in subjects receiving SENS-111, single episodes of dyspepsia and dry mouth were considered possibly related. Among placebo-treated subjects, myalgia and headache were reported as possibly related. Other events were considered as unlikely or not related. There was no indication of dose-dependency for any AEs. Abnormal laboratory values and changes in vital signs and electrocardiogram parameters occurred sporadically, but none considered clinically relevant. Minor deviations in ECG and vital sign assessments were reported that did not affect the quality and validity of the data. There were no deaths, serious AEs or discontinuations due to AEs.
Non-compartmental PK
Estimated PK parameters of the SAD and MAD studies are summarized in Tables S1 and S2 respectively. Single doses of SENS-111 were absorbed relatively rapidly with a median t max ranging from 0.5 to 1.8 h. Plasma concentrations increased dose-proportionally up to 200 mg and more than dose-proportionally at higher doses. Mean plasma concentration-time curves ( Figure S1A) Results of the MAD studies were consistent with the SAD studies. C max were observed after 1-8 h. Plasma concentrations again increased dose-proportionally up to 200 mg after 4-and 7-day repeat doses (Figure S1B and C) . IIV was moderate for both C max and AUC values (from approximately 20% to 35%). t 1/2 after 4 days was similar to that of single dosing (25-28 h) but increased after 7 days of dosing (48-56 h). Some accumulation was observed, with mean AUC 0-24 accumulation ratios of 1.8-2.0 in the 4-day study and 2.6-2.7 for the 7-day study, after 4 and 7 days respectively.
For both single and repeat dosing, plasma concentrations of the SENS-111 metabolites UR-64167 and UR-64250 were quantifiable at all doses (Tables S3 and S4) . For all studies, UR-67147 was present at up to 5% of the parent compound SENS-111 with similar t max and t 1/2 , and concentrations of UR-64250 were up to 1%, with a longer t max and a shorter t 1/2 at 7 days. No associated dose-dependency was apparent.
Functional impact of SENS-111 on nystagmus and vertigo
In both MAD studies, the caloric test induced vertigo and nystagmus at baseline almost systematically, which was mild but measurable but with large inter-and intra-individual variability (15-47% mean of three values per subject). A summary of baseline parameters is provided in Tables 2 and 3 . Inter-and intra-individual variability was high for all parameters; for nystagmus, PSV peak was 35% (mean 23.6°s À1 , range 6.1-63°s À1 ) and 1.2-83.7% respectively, for latency of culmination 17% (mean 78.5 s, range 44-121 s) and 1.2-48.2% respectively, and for nystagmus duration 27% (mean 88 s, range 0-403 s) and 1.6-38.1% respectively. Likewise, in terms of vertigo, inter-and intra-individual variability for latency of appearance were 39% (mean 33 s, range 0-120 s) and 0-52.9% respectively, for duration they were 32% (mean 110 s, range 0-154 s) and 1.1-42.1% respectively, and for latency of disappearance they were 23% (mean 145 s, range 0-350 s) and 0.7-27.7% respectively. For nystagmus, no significant changes were seen over time in subjects treated with SENS-111. For vertigo, significant improvements (P < 0.05) were seen with SENS-111 for all time points grouped vs. baseline for several parameters; latency of vertigo appearance was longer in the 150 mg group, latency of vertigo disappearance was shorter at all dose levels from 50 to 200 mg, duration of vertigo was shorter at dose levels 50, 100, 150 and 250 mg, and vertigo intensity sensation was lower at 100, 150 and 200 mg. For the EEV questionnaire, significant improvements were seen vs. baseline for movement (100, 150 and 200 mg), motion intolerance (150 mg), instability sensation (150, 200 and 250 mg) and total EEV score (50, 100, 150 and 200 mg).
Population PK model
The potential impact of dose and time on clearance and volume was evaluated using a step-wise approach: at each step, one parameter (clearance or volume) was assumed to be affected by one covariate (dose or time). If the LRT indicated a significant contribution of the selected covariate, another covariate was included in the model. The final results of the analysis indicated that both dose and time significantly affected SENS-111 clearance and volume, with clearance and volume expected to decrease with dose increases and with time. The population PK parameter estimates are presented in Table 4 .
Overall, the goodness-of-fit plots ( Figure S2 ) showed no apparent bias suggesting that this model was adequate for describing SENS-111 PK, which was assessed with VPCs using dose-normalized concentrations of SENS-111 (Figure 1 ). In addition to the dose-normalized VPCs, additional VPCs were generated ( Figure S3 ) on the untransformed data to evaluate the adequacy of the model to estimate the time-varying Phase 1 PK/PD study of SENS-111 Table 1 All adverse events in the SAD and MAD studies, by subject 
Population PK/PD model
A descriptive analysis of the relationship between PD measurements and individual level of SENS-111 exposure was conducted prior to formal PK/PD modelling. Placebo data used to develop the PK/PD model are shown for latency of vertigo appearance and disappearance as well as duration of vertigo in Figure S4 . A low and high level of SENS-111 exposure were considered for duration of vertigo (low exposure from 50 to 550 ng ml À1 and high exposure >700 ng ml À1 ), latency of vertigo appearance (low exposure from 100 to 500 ng ml À1 and high exposure >600 ng ml À1 ), latency of vertigo disappearance (low exposure from 100 to 800 ng ml
À1
and high exposure >800 ng ml À1 ). This showed a clear differential response level at low vs. high SENS-111 concentrations ( Figure S5) , with the duration of vertigo reduced from 50 to 550 ng ml À1 and increased from 700 ng ml À1 , the latency of vertigo appearance increased from 100 to 500 ng ml À1 with a reduction from 600 ng ml À1 , and the latency of vertigo disappearance decreased in the range 100-800 ng ml À1 . This behaviour, consistent with preclinical findings [12] , indicated a bell-shaped exposure-response relationship (Figure 2) . The estimated population PK/PD parameters for the latency of vertigo appearance, duration of vertigo and latency of vertigo disappearance are presented in Table 5 . The analysis of the EC501 and EC502 parameters provided some insight into the indirect response mechanism: the estimated values of these parameters indicated that for the latency of vertigo the most robust effect was on the Table 3 Baseline mean ± SD for vertigo parameters for the overall populations in the MAD studies Phase 1 PK/PD study of SENS-111 simulation of k in that occurred at much lower exposure than the simulation of k out . For duration and latency of vertigo, the most robust effect was associated with the inhibition of k in Figure 1 Visual predictive checks (VPCs) on dose-normalized concentrations for (A) single ascending doses (B) and 4-day and (C) 7-day multiple ascending doses. The red lines represent the 5 th , 50 th , and 95 th percentiles of the observed data (orange circles), the shaded grey areas are the 95% confidence intervals of the 5th and 95th percentiles of the simulated data, and the pink shaded areas are the 90% confidence intervals of the 50th percentiles of the simulated data
Figure 2
Visual predictive checks (VPCs) of the PK/PD model for latency of vertigo appearance (A), duration of vertigo (B) and latency of vertigo disappearance (C). The blue lines represent the 5th, 50th and 95th percentiles of the simulated data and the orange circles represent the observed data that occurs at much lower exposure than the inhibition of k out for the two PD parameters. The model showed significance (P < 0.05) for three vertigo parameters. Duration of vertigo was reduced by 27% to 30% (up to 27-28 s) from 50 to 550 ng ml À1 and increased from 700 ng ml À1 . Latency of vertigo appearance increased by 10% to 13% (up to 3 to 4 s) from 100 to 500 ng ml À1 with a reduction from 600 ng ml À1 . Latency of vertigo disappearance decreased by 15% to 20% (up to 20 to 25 s) from 100 to 800 ng ml À1 with no deleterious effects at high concentrations. Finally, simulations of the effective dose and dose regimen for clinical trial validation of the dose regimen are provided for three potential regimens in Figure 3 , showing that twice daily (b.i.d.) administration of SENS-111 on Day 1 achieved steady state rapidly.
Discussion
Symptomatic treatment to mitigate vertigo, dizziness, nausea and vomiting is the cornerstone of management of acute vestibular disorders and notably of AUV, while physical therapy is used to improve central compensation [13] . Anticholinergics, antihistamines and benzodiazepines are administered to counter vertigo and suppress vestibular responses, and antiemetics are used to combat nausea and vomiting [14] . These agents act primarily through sedation or reduction of nausea and are associated with difficulties regulating central compensation. In this setting, the benefits of causal treatment with corticosteroids appear to be limited to accelerating patients' mid-term recovery [15] , without any proven long-term benefit [16] . In this Phase 1 clinical study in healthy men and women volunteers, oral SENS-111 was generally well tolerated at single doses up to 500 mg and with multiple doses up to 250 mg daily for 7 consecutive days. No safety concerns were raised, with all AEs being mild to moderate and resolving before the end of the study, and no apparent dose dependency. Importantly, no sedation or somnolence was reported, even at the highest doses.
The PK profile of SENS-111 and its two metabolites is linear after both single and repeated administrations from 50 to 200 mg but is non-linear (increasing more than doseproportionally) for doses over 250 mg. Moderate IIV is apparent for C max , and AUC of SENS-111 mostly between 20% and 35%, as well as for t max with highly divergent peaks ranging from 0.5 to 8 h across the three sub-studies. Mean t 1/2 for SENS-111 is relatively long, ranging from 25 to 56 h for multiple doses, giving accumulation ratios around 2.0 after 4-day dosing and 2.7 after 7-day dosing. Steady state is achieved after 7-day dosing but is not apparent after 4 days. UR-64167 and UR-64250 exposure correspond to about 5% and 1% of SENS-111 exposure respectively, did not increase or decrease with SENS-111 dose or after repeated administrations, and are not anticipated to have a noticeable clinical impact. Preclinical studies have shown that SENS-111 and its metabolites are excreted in urine and to a lesser extent in bile.
Caloric inductions with warm and cold water (44°C and 30°C) or air (50°C and 24°C) are often used in clinical practice by ENT doctors. This is a diagnostic tool whose primary goal is to assess whether the response to an identical cold or hot stimulus is symmetrical between ears and to evaluate the severity of vestibular dysfunction in the case of imbalance. The caloric test has rarely been used as a pharmacodynamic test either in healthy volunteers or in patients, and is thus not standardized. The effects of drugs used as standard of care in vertigo symptoms such as H 1 histamine receptors antagonists (meclizine, dimenhydrinate) or agonists (betahistine), H 3 receptor antagonists (betahistine) or anticholinergic agents (scopolamine) on parameters related to duration of induced vertigo symptoms (by modified calorics or more cumbersome tests such rotary chair, torsion or parallel swing) including nystagmus, are typically modest (less than 30% improvement) with large variability [17] [18] [19] [20] [21] ; specifically, effects on nystagmus PSV are either mild or absent. In our study, the caloric test was done in healthy volunteers with colder water than usual (25°C instead of 30°C) in only one ear and induced only mild but still measurable nystagmus and vertigo. The use of even colder water (20°C) and/or the repetition of three caloric tests at each time point may enhance vestibular imbalance and reduce the variability in otherwise healthy volunteers. In our study, despite large inter-and intra-individual variability for all nystagmus and vertigo parameters, as is commonly reported for healthy volunteers [22, 23] , significant improvements were seen for vertigo appearance, sensation and disappearance with up to 7 days of repeated SENS-111 administrations compared to baseline for most doses evaluated, although no significant changes were seen for nystagmus over time. The absence of an apparent impact for nystagmus may be accounted for by the very high variability and by the fact that this measurement typically only takes into account a few beats around PSV, whereas the other measures are more continuous.
The modest improvement (20-30%) in vertigo parameters obtained in healthy volunteers with our modified caloric test is consistent with that observed with standard of care treatments [17] [18] [19] [20] [21] and with non-clinical data in rats with severe vestibular dysfunction induced by kainate or arsanilate [12] . A moderate effect on acute vertigo symptoms, such as in AUV, is usually recommended so as to avoid jeopardizing central compensation which is a critical component of effective recovery after acute peripheral loss. In fact, a marked suppression of vertigo symptoms would prevent central compensation and could increase the risk of lasting dizziness and imbalance.
The analysis of the exposure-response relationship shows that the SENS-111 activity is related to plasma concentrations; displaying a bell-shaped curve with a maximum effect at exposures of 200-400 ng ml À1 for latency of vertigo appearance and disappearance and at exposure of 200-600 ng ml À1 for duration of vertigo, with no effect at higher exposure. The bell-shaped response observed for the clinical endpoints was factored into the model, assuming a dual mechanism of action. The initial mechanism, associated with a positive response, was activated at low level of exposure (<600 ng ml
À1
), while the second mechanism accounted for the lack of response at higher exposure. It can be assumed that at high concentrations, the selectivity of the drug for the peripheral H 4 receptor is reduced due to a central effect on vestibular nuclei neurons in the brainstem, which integrate and relay the signal from the peripheral vestibular system through the abducens and oculomotor nuclei to the eye muscles.
The most consistent PD effects are observed from 100 to 200 mg day À1 , corresponding to a mean C max of~100 ng ml
at Day 1 and 170 ng ml À1 at Day 4 with 100 mg, and
Figure 3
Simulated SENS-111 concentrations and change from baseline of the duration of vertigo and the latency of vertigo appearance/disappearance, for three potential dose regimens. The solid blue lines represent the median predictions and the grey shaded areas the 5th and the 95th percentiles of the prediction interval 280 ng ml À1 at Day 1 and 590 ng ml À1 at Day 7 with 200 mg.
PK simulations for potential clinical dose regimens show that steady state is more rapidly obtained when SENS-111 is administered b.i.d. on the first day of treatment. Thus, a treatment regimen of 100 mg or 200 mg SENS-111 b.i.d. on the first day of treatment, followed by once daily administration of the corresponding dose thereafter, should result in the targeted plasma concentrations. The two main limitations of the study are the large inter-and intra-individual variability and the small effect of the caloric test on nystagmus or vertigo parameters; vertigo induced by the caloric test only lasted 110 s and was rated as mild by subjects, which may weaken the translatability of these data to patients suffering from severe vertigo, although the magnitude and effective concentrations correspond to effects seen in a preclinical rat model of severe vertigo [12] . As the use of placebo in this study was only designed to ensure that subjects and the investigator were blinded, the sample size of placebo-treated subjects is too small and the IIV too large to adequately compare SENS-111 vs. placebo. Despite these limitations, the PK/PD relationship identified offers some degree of confidence in terms of the robustness of the data, which were consistent with those obtained in animal models.
In conclusion, oral SENS-111 is safely administered clinically as single and once daily repeated doses up to 250 mg day À1 for 7 days. The absence of sedation or somnolence combined with the PK/PD modelling and simulation identifying the 100 and 200 mg day À1 repeated doses as suitable dose regimens, support the evaluation of SENS-111 as symptomatic treatment of vestibular disorders, notably in patients suffering from AUV, for whom no effective nonsedative treatments are available.
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